Keyphrases
Acute Myeloid Leukemia
100%
Novel Agents
100%
Older Adults
80%
Anthracyclines
40%
Complete Remission
40%
Cytarabine
40%
Signal Transduction Pathway
20%
Histone Deacetylase Inhibitor (HDACi)
20%
Overexpression
20%
Protease Inhibitors
20%
Specific Genes
20%
Gene mutation
20%
New Therapeutic Strategies
20%
Leukemic Cells
20%
Outcome Prediction
20%
B-cell Lymphoma 2 (Bcl-2)
20%
Disease-free
20%
Nucleoside Analogues
20%
Cytotoxic Drugs
20%
Multidrug Resistance
20%
Inhibitor of Apoptosis Proteins
20%
Working Diagnosis
20%
FMS-like Tyrosine Kinase 3 (FLT3)
20%
Farnesyltransferase Inhibitor
20%
Transporter Proteins
20%
Long-term Survivors
20%
Surface Antigen
20%
Cytotoxic Agents
20%
Daunorubicin
20%
Immunoconjugate
20%
EVI1
20%
Idarubicin
20%
Mitoxantrone
20%
Transmembrane Transporter
20%
Gemtuzumab Ozogamicin
20%
High-dose Cytarabine
20%
FLT3 Inhibitor
20%
Conventional Dose
20%
Anthracenedione
20%
Angiogenesis Inducing Agents
20%
Antiangiogenesis Agents
20%
Multidrug Resistance Inhibitors
20%
BAALC
20%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Cytarabine
60%
Anthracycline
40%
Cytotoxic Agent
40%
Multidrug Resistance
40%
Diseases
20%
Drug Megadose
20%
Gene Mutation
20%
Angiogenesis Inhibitor
20%
Liposomal Daunorubicin
20%
Signal Transduction Pathway
20%
Membrane Antigen
20%
Idarubicin
20%
Gemtuzumab Ozogamicin
20%
Farnesyltransferase Inhibitor
20%
Apoptosis Inhibitor
20%
CCAAT Enhancer Binding Protein Alpha
20%
Karyotype
20%
Histone Deacetylase
20%
Mitoxantrone
20%
Anthraquinone
20%
Nucleoside Analog
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Cytarabine
60%
Remission
40%
Cytotoxic Agent
40%
Anthracycline
40%
Multidrug Resistance
40%
Daunorubicin
20%
Nucleoside Analog
20%
Mitoxantrone
20%
Anthraquinone
20%
Carrier Protein
20%
Idarubicin
20%
Apoptosis Inhibitor
20%
Gemtuzumab Ozogamicin
20%
Protein Farnesyltransferase Inhibitor
20%
Membrane Antigen
20%
Disease
20%
CCAAT Enhancer Binding Protein Alpha
20%
Angiogenesis Inhibitor
20%
Histone Deacetylase
20%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Cytarabine
60%
Multidrug Resistance
40%
Anthracycline
40%
Signal Transduction
20%
Karyotype
20%
WT1
20%
Transmembrane Transporters
20%
Farnesyltransferase
20%
CCAAT Enhancer Binding Protein Alpha
20%
Gene Mutation
20%
Drug Megadose
20%
Antiangiogenic Activity
20%
Daunorubicin
20%
Idarubicin
20%
Histone Deacetylase
20%
Gemtuzumab Ozogamicin
20%
Carrier Protein
20%
Nucleoside Analog
20%